These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9484761)

  • 1. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.
    van Gelder T; Baan CC; Balk AH; Knoop CJ; Holweg CT; van der Meer P; Mochtar B; Zondervan PE; Niesters HG; Weimar W
    Transplantation; 1998 Feb; 65(3):405-10. PubMed ID: 9484761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redundancy of the cytokine network in the development of rejection after clinical heart transplantation.
    Baan CC; Holweg CH; van Gelder T; Knoop CJ; Niesters HG; Zondervan P; Mochtar B; Balk AH; Weimar W
    Transpl Int; 1998; 11 Suppl 1():S512-4. PubMed ID: 9665048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.
    van Gelder T; Balk AH; Jonkman FA; Zietse R; Zondervan P; Hesse CJ; Vaessen LM; Mochtar B; Weimar W
    Transplantation; 1996 Jul; 62(1):51-5. PubMed ID: 8693545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation.
    Baan CC; Knoop CJ; van Gelder T; Holweg CT; Niesters HG; Smeets TJ; van der Ham F; Zondervan PE; Maat LP; Balk AH; Weimar W
    Transplantation; 1999 Mar; 67(6):870-6. PubMed ID: 10199736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation.
    van Gelder T; Zietse R; Mulder AH; Yzermans JN; Hesse CJ; Vaessen LM; Weimar W
    Transplantation; 1995 Aug; 60(3):248-52. PubMed ID: 7645037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
    Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
    Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation.
    Hesse CJ; van Gelder T; Vaessen LM; Knoop CJ; Balk AH; Yzermans JN; Jutte NH; Weimar W
    Immunopharmacology; 1995 Sep; 30(3):237-46. PubMed ID: 8557524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
    Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
    Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
    [No Abstract]   [Full Text] [Related]  

  • 13. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
    Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
    Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid resistance in clinical heart transplantation: the role of simultaneous IL-2 and IL-4 mRNA expression.
    Baan CC; Niesters HG; Balk AH; Mochtar B; Zondervan PE; van Gelder T; Weimar W
    Transplant Proc; 1996 Dec; 28(6):3239-40. PubMed ID: 8962254
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
    van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
    Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
    Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
    Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
    Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.